Page last updated: 2024-11-04

rolipram and Uveitis

rolipram has been researched along with Uveitis in 1 studies

Uveitis: Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed)

Research Excerpts

ExcerptRelevanceReference
"Rolipram treatment from days -1 to 7 after immunization (afferent phase) was not protective, but severity of EAU was reduced to 50% by treatment from days 8 to 16 after immunization or when EAU was induced by adoptive transfer (efferent phase)."1.30Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity. ( Caspi, RR; Chan, CC; Rizzo, LV; Silver, PB; Strassmann, G; Wiggert, B; Xu, H, 1999)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Xu, H1
Strassmann, G1
Chan, CC1
Rizzo, LV1
Silver, PB1
Wiggert, B1
Caspi, RR1

Other Studies

1 other study available for rolipram and Uveitis

ArticleYear
Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
    Investigative ophthalmology & visual science, 1999, Volume: 40, Issue:5

    Topics: Adoptive Transfer; Animals; Autoimmune Diseases; DNA Primers; Dose-Response Relationship, Drug; Eye

1999